Companies · NVST
Envista Holdings
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 19, 2026
Envista elevates Paul Keel to Chairman; awards $10M special equity package to CEO.
Envista appointed Paul Keel, President and Chief Executive Officer since May 2024, to the role of Chairman of the Board effective August 19, 2026, in a move the Board characterized as strengthening strategic alignment and long-term value creation. Keel received a special one-time equity award valued at $10 million split between $5 million in time-based RSUs and $5 million in PSUs tied to four-year relative TSR performance against the S&P 400 Health Care Sector Index, plus a $200,000 base salary increase to $1.3 million annually. CFO Eric Hammes received a separate $1.5 million PSU award under the same TSR performance condition.
Tone: neutralRevenue
$2.7B
NVST 10-K · FY 2025
Employees
12,000
Revenue FY2024
$2.5B
Founded
2018
Profile
NVST 10-K Item 1 · Feb 12, 2026Envista Holdings is a global dental products company operating more than 30 brands across dental implants, orthodontics, digital imaging, and consumable dental supplies. The company serves dental professionals in over 130 countries through a direct commercial organization and distribution partners. In 2025, it generated $2.7 billion in total sales, with approximately 85% derived from consumable products, services, and spare parts.
Read filing description ↓ Collapse description ↑
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile. We further support the dental community with leading solutions in restoratives, endodontics, rotary, infection prevention, and loupes. With a foundation comprised of the proven Envista Business System ('EBS') methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, we are well equipped to meet the end-to-end needs of dental professionals worldwide. We are one of the largest global dental products companies, with strong positions in some of the most attractive segments of the dental products industry. We serve dental professionals in over 130 countries through one of the largest commercial organizations in the dental products industry and through our distribution partners. In 2025, we generated total sales of $2.7 billion, of which approximately 85% were derived from sales of consumable products, services, and spare parts. Our business is operated through two segments: Specialty Products & Technologies, which is comprised of our Dental Implant Solutions and Orthodontic Solutions businesses, and Equipment & Consumables, which is comprised of our Diagnostic and Consumables Solutions businesses.
Primary products
- Dental implant systems
- Guided surgery systems
- Biomaterials
- Prefabricated and custom-built prosthetics
- Orthodontic bracket systems
- Clear aligners (Spark)
Business segments
End markets
Geographies
Named customers
One customer, Henry Schein, Inc. ('Henry Schein'), accounted for approximately 12% of our sales for 2025 and 10% of our sales for 2024 and 2023. Other than Henry Schein, no single customer accounted for more than 10% of combined sales in 2025, 2024, or 2023.
“We are one of the largest global dental products companies, with strong positions in some of the most attractive segments of the dental products industry.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total sales grew from $2,510.6 million in 2024 to $2,719.5 million in 2025, with the Specialty Products & Technologies segment reporting year-over-year sales growth of 8.4% and core sales growth of 6.3%.
The rest of NVST is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.